RVNC News and Press, Revance Therapeutics Inc. From 06/04/19

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Pa...

Fresh after the company rejected the idea of replacing its CEO, markets continue to send shares of Allergan ( AGN ) lower. At a recent price of $133, markets signal a lack of confidence in the company's future. The stock trades at a forward P/E of below 8 times, while the stock offers a di...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Healthcare Conference in New York, NY. ...

Seanergy Maritime Holdings (NASDAQ: SHIP )  -48%  on pricing stock offering. More news on: Seanergy Maritime Holdings Corp., Stamps.com Inc., Mer Telemanagement Solutions Ltd., Stocks on the move, Read more ...

Revance Therapeutics, Inc. (RVNC) Q1 2019 Earnings Conference Call May 08, 2019, 16:30 ET Company Participants Jeanie Herbert - Senior Director, IR & Corporate Communications Daniel Browne - Co-Founder, President, CEO & Director Tobin Schilke - CFO & Principal Account...

Revance Therapeutics (NASDAQ: RVNC ) announces Q1 results . Highlights: Revenue: $278K; net loss: ($35.3M). More news on: Revance Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Revance Therapeutics (NASDAQ: RVNC ): Q1 GAAP EPS of -$0.85 beats by $0.08 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today reported financial results for the quarter ended March 31...

Conference Call Scheduled for Wednesday, May 8, 2019 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will release fi...

– Unprecedented clinical results for DaxibotulinumtoxinA for Injection (DAXI), Revance’s long-acting neuromodulator, were highlighted at the 17 th Aesthetics & Anti-Aging Medical World Congress in Monte-Carlo – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biote...